Breath nitric oxide testing to help manage asthma in children
Tests whether breath nitric oxide monitoring improves asthma care in children.
Plain-language title generated from the registry record
Registry title: This Study Aims to Compare Asthma Control in Children Monitored With FeNO Against a Historical Cohort Without FeNO. Secondary Objectives Include Evaluating Associations Between FeNO Levels, ACT/C-ACT Scores, Eosinophil Counts, FEV1%, ICS Adherence, and Exacerbation Frequency.
Key facts
- Where
- Jeddah, Saudi ArabiaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 14 years old?
Source: NCT07788534, who can take part
Where in Saudi Arabia
- king Faisal specialized hospital and research centerJeddah, Saudi ArabiaTaking people
- King Faisal Sepiclaized Hospital and Research CenterJeddah, Saudi ArabiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King Faisal Specialist Hospital & Research Center
- Trial code
- NCT07788534
- Record updated
- 26 August 2026
- Original description
This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNORead full original descriptionShow less
FeNO Fractional Exhaled Nitric Oxide Test as Significant Tool in Enhancing Asthma Treatment Management Among Children
This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNO
Inclusion: Children aged 6 to 14 years with a physician-diagnosed asthma; Minimum of three months' follow-up at the pediatric respiratory clinic; Availability of Asthma Control Test (ACT/C-ACT) scores and clinical data.
Exclusion: Presence of other chronic pulmonary diseases (e.g., cystic fibrosis); Recent respiratory infections within four weeks prior to enrollment; Current treatment with biologic agents affecting asthma inflammation.